ArticleFrontiers in cellular and infection microbiology2026
Molecular epidemiological association between antimicrobial resistance characteristics and type III secretion system in carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Objective: This study investigated the antimicrobial resistance profile of carbapenem-resistant Methods: Retrospective cohort study was performed with CRPA lower respiratory tract infection from a tertiary hospital (July, 2021, and May, 2025). All strains underwent whole-genome sequencing (WGS), antimicrobial susceptibility testing(AST); selected isolates' virulence were further evaluated using galleria mellonella infection assays. Results: Among 106 patients caused by CRPA infections, the majority were male (73.6%), with a median age of 69.5 years and median hospital stay of 26.5 days. Prior antibiotic exposure included piperacillin/tazobactam (57.5%) and carbapenems (49.1%). AST revealed high resistance to piperacillin/tazobactam, but favorable susceptibility to ceftazidime/avibactam and tobramycin, with no polymyxin B resistance. Multidrug resistance occurred in 49.1% of isolates, and 28.3% were difficult-to-treat Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.